Edition:
United Kingdom

Profile: Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

119.80USD
18 Apr 2019
Change (% chg)

$-1.23 (-1.02%)
Prev Close
$121.03
Open
$122.34
Day's High
$122.34
Day's Low
$117.18
Volume
171,023
Avg. Vol
126,238
52-wk High
$220.09
52-wk Low
$105.19

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. Its cancer biology platform addresses the position of tumor-immune system interactions and the value of primary biopsies in developing new models.

BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). The Company is developing BGB-3111 as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members, namely poly ADP ribose polymerase 1 (PARP1) and poly ADP ribose polymerase 2 (PARP2). The Company is developing BGB-290 as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers.

BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. The Company is developing BGB-283 for the treatment of cancers with aberrations in the mitogen-activated protein kinase (MAPK), pathway, including BRAF gene mutations and KRAS/NRAS gene mutations where first generation BRAF inhibitors are not effective.

BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1. The Company is developing BGB-A317 as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. BGB-A317 is a monoclonal antibody designed to specifically bind to PD-1, thereby preventing PD-L1, a signaling protein, from engaging PD-1.

The Company competes with Bristol-Myers Squibb Co., Ono Pharmaceutical Co./Gilead, Janssen/AbbVie, Inc., Merck KGaA, AstraZeneca PLC/Celgene, Roche, Pfizer, Darmstadt Germany, Regeneron, Tesaro, Incyte/Hengrui, Innovent Bio, Junshi, Clovis Oncology, Abbott, Jiangsu Hansoh, Jiangxi Qingfeng, GSK, Array Biopharma, Takeda, Daiichi Sankyo and Zhejiang Daoming BioPharma.

Company Address

Beigene Ltd

C/O Mourant Governance Services
94 Solaris Avenue, Camana Bay
GRAND CAYMAN     KY1-1108
P: +1345.9494123

Company Web Links